• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

作者信息

Thota Swapna, Patel Bhumika J, Sadaps Meena, Balasubramanian Suresh, Sanikommu Srinivasa, Hirsch Cassandra, Marotta Serena, Sekeres Mikkael A, Risitano Antonio M, Maciejewski Jaroslaw P

机构信息

Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland, OH, USA.

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA.

出版信息

Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14.

DOI:10.1111/bjh.14907
PMID:28905372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8404554/
Abstract
摘要

相似文献

1
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.皮下注射低剂量阿仑单抗治疗获得性骨髓衰竭疾病的疗效
Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14.
2
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.伴有 T 细胞大颗粒淋巴细胞白血病的难治性纯红细胞再生障碍性贫血经芦可替尼治疗。
Ann Hematol. 2024 Aug;103(8):3239-3242. doi: 10.1007/s00277-024-05856-z. Epub 2024 Jun 27.
3
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).使用抗CD52单克隆抗体阿仑单抗（Campath-1H）成功治疗与淋巴增殖性疾病相关的难治性纯红细胞再生障碍性贫血。
Br J Haematol. 2003 Oct;123(2):278-81. doi: 10.1046/j.1365-2141.2003.04609.x.
4
Rational management approach to pure red cell aplasia.纯红细胞再生障碍性贫血的合理治疗方法。
Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.
5
A portion of expanded granular lymphocytes cause pure white cell aplasia?一部分扩增的颗粒淋巴细胞会导致纯白细胞再生障碍吗？
Ann Hematol. 2018 Oct;97(10):1995-1997. doi: 10.1007/s00277-018-3342-5. Epub 2018 May 2.
6
A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.一项针对骨髓衰竭综合征患者的阿仑单抗联合环孢素的剂量递增试验性研究。
Leuk Res. 2009 Feb;33(2):222-31. doi: 10.1016/j.leukres.2008.08.004. Epub 2008 Sep 14.
7
Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia.低剂量皮下注射阿仑单抗治疗慢性获得性纯红细胞再生障碍性贫血安全有效。
Hong Kong Med J. 2013 Dec;19(6):549-52. doi: 10.12809/hkmj133798.
8
Distinct effect of cyclophosphamide and cyclosporine on pure red cell aplasia associated with T-cell large granular lymphocyte leukemia.环磷酰胺和环孢素对与T细胞大颗粒淋巴细胞白血病相关的纯红细胞再生障碍性贫血的不同作用。
Int Immunopharmacol. 2014 Dec;23(2):391-4. doi: 10.1016/j.intimp.2014.10.013.
9
[Successful treatment of pure red cell aplasia with cyclosporin in a patient with T-cell large granular lymphocytic leukemia harboring the STAT3 D661V mutation].[环孢素成功治疗一名携带STAT3 D661V突变的T细胞大颗粒淋巴细胞白血病患者的纯红细胞再生障碍性贫血]
Rinsho Ketsueki. 2019;60(1):39-45. doi: 10.11406/rinketsu.60.39.
10
Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure.口服环孢素A对未经治疗以及先前接受过免疫抑制治疗的严重骨髓衰竭患者均是有效的治疗方法。
Eur J Haematol. 1989 Aug;43(2):136-42. doi: 10.1111/j.1600-0609.1989.tb00269.x.

引用本文的文献

1
Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature review.免疫介导性血细胞减少症中抗胸腺细胞球蛋白的单中心经验及文献综述
Br J Haematol. 2025 Jun 12;207(1):284-8. doi: 10.1111/bjh.20165.
2
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.门诊皮下注射阿仑单抗治疗再生障碍性贫血是可行且安全的，并且缓解率高。
Blood Adv. 2025 Feb 25;9(4):906-912. doi: 10.1182/bloodadvances.2024014159.
3
Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment.大颗粒淋巴细胞白血病：临床特征、分子发病机制、诊断与治疗
Cancers (Basel). 2024 Mar 27;16(7):1307. doi: 10.3390/cancers16071307.
4
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.阿仑单抗治疗复发型免疫性重型再生障碍性贫血：一项 II 期研究的长期结果。
Am J Hematol. 2023 Jun;98(6):932-939. doi: 10.1002/ajh.26924. Epub 2023 Apr 6.
5
Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease.大颗粒淋巴细胞白血病：从免疫发病机制到难治性疾病的治疗
Cancers (Basel). 2021 Sep 1;13(17):4418. doi: 10.3390/cancers13174418.
6
How I manage acquired pure red cell aplasia in adults.成人获得性纯红细胞再生障碍性贫血的治疗策略。
Blood. 2021 Apr 15;137(15):2001-2009. doi: 10.1182/blood.2021010898.
7
[Chinese expert consensus on the diagnosis and treatment of acquired pure red cell aplasia (2020)].《获得性纯红细胞再生障碍性贫血诊断与治疗中国专家共识（2020年版）》
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):177-184. doi: 10.3760/cma.j.issn.0253-2727.2020.03.001.
8
Aplastic Anemia.再生障碍性贫血
N Engl J Med. 2018 Oct 25;379(17):1643-1656. doi: 10.1056/NEJMra1413485.
9
Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis.一名接受阿仑单抗治疗多发性硬化症的患者发生获得性甲型血友病。
BMJ Case Rep. 2018 Oct 17;2018:bcr-2018-226588. doi: 10.1136/bcr-2018-226588.
10
Rational management approach to pure red cell aplasia.纯红细胞再生障碍性贫血的合理治疗方法。
Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.

本文引用的文献

1
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.阿仑单抗治疗T细胞大颗粒淋巴细胞白血病：一项单臂、开放标签的2期研究的中期结果。
Lancet Haematol. 2016 Jan;3(1):e22-9. doi: 10.1016/S2352-3026(15)00227-6. Epub 2015 Dec 17.
2
Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).来那度胺在伴有纯红细胞再生障碍性贫血（PRCA）的5号染色体长臂缺失（del(5q)）的骨髓增生异常综合征治疗中的作用。
Ann Hematol. 2015 Mar;94(3):531-4. doi: 10.1007/s00277-014-2192-z. Epub 2014 Aug 20.
3
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).在不能进行移植且对抗胸腺细胞球蛋白免疫抑制治疗失败的患者中，采用其他免疫抑制药物治疗：坎帕斯（阿仑单抗）。
Bone Marrow Transplant. 2013 Feb;48(2):186-90. doi: 10.1038/bmt.2012.245. Epub 2012 Dec 10.
4
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.阿仑单抗单药治疗初治、复发和难治性重型获得性再生障碍性贫血的疗效。
Blood. 2012 Jan 12;119(2):345-54. doi: 10.1182/blood-2011-05-352328. Epub 2011 Nov 8.
5
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.阿仑单抗作为免疫抑制治疗再生障碍性贫血和单一谱系骨髓衰竭症是安全有效的：来自 EBMT WPSAA 的一项试点研究和调查。
Br J Haematol. 2010 Mar;148(5):791-6. doi: 10.1111/j.1365-2141.2009.08027.x. Epub 2009 Dec 7.
6
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.CD8+ 大颗粒淋巴细胞白血病中克隆性细胞毒性 T 细胞 CD52 可变表达的治疗意义。
Haematologica. 2009 Oct;94(10):1407-14. doi: 10.3324/haematol.2009.009191.
7
Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia.皮下注射阿仑单抗联合环孢素治疗再生障碍性贫血。
Ann Hematol. 2010 Mar;89(3):299-303. doi: 10.1007/s00277-009-0816-5. Epub 2009 Aug 25.
8
A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.一项针对骨髓衰竭综合征患者的阿仑单抗联合环孢素的剂量递增试验性研究。
Leuk Res. 2009 Feb;33(2):222-31. doi: 10.1016/j.leukres.2008.08.004. Epub 2008 Sep 14.
9
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.Campath-1H治疗自身免疫性血细胞减少症患者的疗效。
Br J Haematol. 2001 Sep;114(4):891-8. doi: 10.1046/j.1365-2141.2001.03039.x.
10
The pathophysiology of acquired aplastic anemia.获得性再生障碍性贫血的病理生理学。
N Engl J Med. 1997 May 8;336(19):1365-72. doi: 10.1056/NEJM199705083361906.